Lung Cancer Considered

In this special WCLC 2026 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu recap key findings from day three of the conference, featuring major advances that move targeted therapies earlier in the treatment of lung cancer.

Guests Dr. Julia Rotow, Dr. Roy Herbst, and Dr. Daniel Tan discuss new data from DESTINY-Lung04, ADAURA, and REZILIENT3 and what these findings could mean for clinical practice.

Guests:
Dr. Julia Rotow
Clinical Director and Research Director, Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute


Dr. Roy Herbst
Director, Dartmouth Cancer Center
Professor, Geisel School of Medicine at Dartmouth

Dr. Daniel Shao-Weng Tan
Senior Consultant Medical Oncologist at Division of Medical Oncology, National Cancer Centre Singapore
Professor, Duke-NUS Medical School
Senior Clinician-Scientist, Genome Institute of Singapore

The 2026 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research.

To reach a global audience, IASLC has recorded podcast episodes on WCLC 2026 in world languages.

In this episode, host Dr. Chunxia Su moderates a discussion in Mandarin Chinese about breakthrough advances in thoracic oncology presented at the conference with Dr. Zhengfei Zhu, Dr. Yun Fan, and Dr. Dongsheng Yue.

Guests:
Dr. Yun Fan, MD, PhD
Chief Expert of the Multidisciplinary Lung Cancer Team, Zhejiang Cancer Hospital;
Senior Consultant (Grade II Chief Physician); Doctoral Supervisor

Dr. Dongsheng Yue, MD, PhD
Tianjin Medical University Cancer Institute and Hospital

Dr. Zhengfei Zhu, MD, PhD
Department of Radiation Oncology
Fudan University Shanghai Cancer Center

In this special WCLC 2026 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu discuss daily highlights from the conference and ask what changes in clinic on Monday.

A ROS1 drug that protects the brain and a first line combination that could not beat a decade old standard. Dr. Alexander Drilon brings the first line ARROS-1 data on zidesamtinib, and Dr. Giannis Mountzios walks us through EVOKE-03, sacituzumab govitecan plus pembrolizumab in PD-L1 high lung cancer.

Guests:

Alexander Drilon, MD
Chief, Early Drug Development Service
Memorial Sloan Kettering Cancer Center
Professor, Weill Cornell Medical College
Attending Physician, Thoracic Oncology Service

Giannis Mountzios, MD, MSc, PhD
Medical Oncologist and Director at the 4th Oncology Department and Clinical Trials Unit
Henry Dunant Hospital Center
Athens, Greece,

From the IASLC 2026 World Conference on Lung Cancer (WCLC) in Seoul, Dr. Narjust Florez talks with Dr. Chad Rusthoven about MAVERICK, the trial that tested MRI surveillance alone against prophylactic cranial irradiation in small cell lung cancer, and with Dr. Chul Kim about the final overall survival results of PAPILLON, amivantamab plus chemotherapy in EGFR exon 20 insertion NSCLC.

Both guests share what patients and community oncologists should take from the data.

Guests:

Chul Kim, MD, MPH
Thoracic Medical Oncologist and Associate Professor
Georgetown University

Chad G. Rusthoven, MD
Adjunct Associate Professor
University of Colorado
University of North Carolina at Chapel Hill

Get ready for WCLC 2026 in Seoul with Lung Cancer Considered hosts Dr. Stephen Liu and Dr. Narjust Florez. From preparing for the flight and beating jet lag to navigating COEX, networking, exploring Seoul’s food scene, and making the most of the meeting, they share practical tips to help attendees arrive prepared and enjoy the full WCLC experience.